Cytotoxic, Antitumour, and Chemopreventive Potential of Cnidoscolus Species: Experimental Evidence, Mechanisms, and Meta-Analysis
Аннотация
Species of the genus Cnidoscolus Pohl, Euphorbiaceae, including Chaya ( C. aconitifolius ), are widely used in traditional medicine across Latin America for managing diabetes, inflammation, and gastrointestinal disorders. Despite increasing interest in their phytochemical composition and ethnopharmacological relevance, their cytotoxic and antitumour potential has not been systematically evaluated. This study aimed to systematically review and meta-analyse experimental evidence on the growth-inhibitory activity of Cnidoscolus species, focusing on species and plant parts investigated, tumour cell line sensitivity, underlying molecular mechanisms, and extract-related efficacy. A systematic review was conducted following PRISMA 2020 guidelines. Database searches (PubMed, Scopus, Web of Science, Embase; inception–April 2026) identified eligible in vitro cytotoxic and in vivo antitumour or chemopreventive studies. Two independent reviewers performed screening, data extraction, and quality assessment. Quantitative synthesis used a random-effects model with the DerSimonian–Laird estimator. Effect sizes were expressed as growth inhibition or cell mortality percentages, and heterogeneity was assessed using I 2 , Cochran’s Q , and τ 2 . A total of 272 records were identified, with five studies (four experimental and one review) included in the qualitative synthesis and seven study arms in the meta-analysis. The pooled inhibition estimate was 56.2% (95% CI 45.7–66.7%), with substantial heterogeneity ( I 2 = 89.0%). Reported IC 50 and LC 50 values ranged from 15.05 to 5.28 mg/ml across different preparations and experimental models. Mechanistic evidence indicated apoptosis associated with caspase-3 activation, G 0 /G 1 and S-phase cell-cycle alterations, tubulin depolymerization, and photodynamic singlet oxygen generation. Overall, Cnidoscolus species exhibit promising preclinical cytotoxic, antitumour, and chemopreventive activities. However, the available evidence remains limited, predominantly in vitro , and heterogeneous across experimental models and outcome measures, with insufficient selectivity and toxicological data. Further in vivo evaluation, pharmacokinetic characterization, and safety assessments are needed to clarify their potential for clinical translation. Graphical Abstract